FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain
The FDA approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic to treat moderate to severe acute pain in adults.
The FDA approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic to treat moderate to severe acute pain in adults.
Information on topics such as gender, teens’ behavior, and infectious diseases was removed from the CDC’s website.
Here’s why the U.S. FDA kicked off 2025 with a ban on red dye 3, saying this common food dye must be removed from all…
LIKE US ON FACEBOOK TO STAY INFORMED ABOUT FUTURE PROJECTS facebook.com/GlobalBEMGlobalBEM 2013 Title: Vortex Based MathematicsWant to see more than 50 other…
A former F.D.A. commissioner thinks we’ve ignored two crucial avenues that are fueling the opioid crisis.
Nevada will soon join Colorado and Washington as the only states offering “public option” health plans on their insurance exchanges. More may follow.
Chains of smaller, specialized AI agents aren’t just more efficient — they will help solve problems in ways we never imagined.
Crimean-Congo hemorrhagic fever virus is a widespread tickborne virus that infects humans. Engineering-based structural studies of the viral glycoprotein complexes GP38-Gn and GP38-Gn-Gc provide insights…
OpenAI has released a new proprietary AI model in time to counter the rapid rise of open source rival DeepSeek-R1 — but will it be…
Information on topics such as gender, teens’ behavior, and infectious diseases was removed from the CDC’s website.
Cleveland Clinic is participating in new research that centers on the use of engineered T cells to support the immune system in directly targeting ovarian…